PACTG 1020-A (VERSION 20):PHASE I/II STUDY OF A NOVEL PROTEASE INHIBITOR IN HIV

PACTG 1020-A（版本 20）：新型蛋白酶抑制剂治疗 HIV 的 I/II 期研究

• 批准号: 7605839
• 负责人: William Thomas Shearer
• 金额: $ 1.79万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605839
• 关键词: Adolescent; Age; Anti-Retroviral Agents; BMS232632; Calendar; Child; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV; Infant; Institution; Label; Multicenter Studies; Phase; Protease Inhibitor; Research; Research Personnel; Resources; Sample Size; Source; Treatment Protocols; United States National Institutes of Health; day; experience; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Phase I/II, open-label multicenter study of BMS-232632 as part of combination antiretroviral regimens. The sample size will be a minimum of 72 subjects and will include HIV-infected infants, children, and adolescents ages 3 calendar months and 1 day to 21 years, who are either ART-nanve or ART-experienced.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 I/II期，BMS-232632的开放标签多中心研究，作为组合抗逆转录病毒方案的一部分。样本量至少为72个受试者，包括感染HIV的婴儿，儿童和青少年3个日历月和1天至21岁，他们都是艺术或经验丰富的。